{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=7", "query": { "condition": "Melanoma", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 2273, "total_pages": 228, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T01:37:25.358Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03005639", "title": "ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IIIB-C Melanoma" ], "interventions": [ { "name": "Vemurafenib and Cobimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inova Health Care Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-06-01", "completion_date": "2018-02-24", "has_results": false, "last_update_posted_date": "2018-05-09", "last_synced_at": "2026-10-23T01:37:25.358Z", "location_count": 1, "location_summary": "Fairfax, Virginia", "locations": [ { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03005639" }, { "nct_id": "NCT00403377", "title": "Investigation of a Behavioral Substitute for Sunbathing", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma (Skin)", "Skin Cancer" ], "interventions": [ { "name": "Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Massachusetts, Worcester", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 307, "start_date": "2006-04", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2015-10-01", "last_synced_at": "2026-10-23T01:37:25.358Z", "location_count": 1, "location_summary": "Worcester, Massachusetts", "locations": [ { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00403377" }, { "nct_id": "NCT01522664", "title": "A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "DEDN6526A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2012-03", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-23T01:37:25.358Z", "location_count": 4, "location_summary": "Los Angeles, California • Sarasota, Florida • Detroit, Michigan + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01522664" }, { "nct_id": "NCT03589339", "title": "NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Radiotherapy", "Immunotherapy", "Microsatellite Instability-High Solid Malignant Tumour", "Metastasis From Malignant Tumor of Liver", "Squamous Cell Carcinoma of Head and Neck", "Metastasis From Malignant Tumor of Cervix", "Metastatic Renal Cell Carcinoma", "Metastasis From Malignant Melanoma of Skin (Disorder)", "Metastatic Triple-Negative Breast Carcinoma", "Metastatic NSCLC", "Metastasis From Malignant Tumor of Bladder (Disorder)" ], "interventions": [ { "name": "NBTXR3", "type": "DRUG" }, { "name": "SABR", "type": "RADIATION" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Nanobiotix", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2019-01-16", "completion_date": "2027-08-30", "has_results": false, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-10-23T01:37:25.358Z", "location_count": 13, "location_summary": "San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03589339" }, { "nct_id": "NCT02702492", "title": "PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "NHL" ], "interventions": [ { "name": "KPT-9274", "type": "DRUG" }, { "name": "Niacin ER", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2016-06-08", "completion_date": "2021-01-26", "has_results": true, "last_update_posted_date": "2024-11-25", "last_synced_at": "2026-10-23T01:37:25.358Z", "location_count": 7, "location_summary": "Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02702492" }, { "nct_id": "NCT00661336", "title": "A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "buthionine sulfoximine", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "high performance liquid chromatography", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2008-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-03-13", "last_synced_at": "2026-10-23T01:37:25.358Z", "location_count": 2, "location_summary": "Durham, North Carolina • Houston, Texas", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00661336" }, { "nct_id": "NCT07237100", "title": "Mirdametinib in Patients With Advanced NF1-mutant Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Unresectable Melanoma", "Metastatic Melanoma" ], "interventions": [ { "name": "Mirdametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kevin Kim, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2025-10-13", "completion_date": "2030-10-13", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-10-23T01:37:25.358Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07237100" }, { "nct_id": "NCT01460134", "title": "A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma", "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma", "Marginal Zone B Cell Lymphoma)", "Any T-cell Malignancy", "Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma", "Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer", "Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)", "Burkett's Lymphoma", "Primary Lymphoma of the Central Nervous System" ], "interventions": [ { "name": "CDX-1127", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2011-10", "completion_date": "2017-10-16", "has_results": false, "last_update_posted_date": "2018-01-31", "last_synced_at": "2026-10-23T01:37:25.358Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01460134" }, { "nct_id": "NCT00004244", "title": "Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kidney Cancer", "Melanoma (Skin)" ], "interventions": [ { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "recombinant interleukin-12", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2000-03", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2013-03-21", "last_synced_at": "2026-10-23T01:37:25.358Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004244" }, { "nct_id": "NCT00104988", "title": "S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2005-06", "completion_date": "2009-08", "has_results": false, "last_update_posted_date": "2012-08-22", "last_synced_at": "2026-10-23T01:37:25.358Z", "location_count": 132, "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • Castro Valley, California + 89 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Castro Valley", "state": "California" }, { "city": "Fairfield", "state": "California" }, { "city": "Hayward", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104988" } ] }